Intoplicine

N/A

Report date: 2023/08/27 20:00:33
NME

Base Information

Drug NameIntoplicine
Drug Alias Name茚托利辛intoplicinumintoplicinaintoplicineNSC-D-645008 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTopoisomerase II inhibitorsDNA topoisomerase I inhibitors
TargetsTopoisomerase IIDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofiGenzyme Corp
Active IndicationsN/A
Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A